Bridgeway Capital Management’s Climb Bio CLYM Stock Holding History

Bridgeway Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.7M	Sell	130,300 -4,000	-3%	-$41.3K	0.03%	613
2026 Q1	$920K	Sell	134,300 -25,000	-16%	-$144K	0.02%	720
2025 Q4	$637K	Buy	159,300 +50,000	+46%	+$120K	0.01%	780
2025 Q3	$220K	Sell	109,300 -25,000	-19%	-$46.4K	﹤0.01%	997
2025 Q2	$167K	Hold	134,300	–	–	﹤0.01%	996
2025 Q1	$164K	Buy	+134,300	New	+$218K	﹤0.01%	958
2024 Q3	–	Sell	-55,223	Closed	-$393K	–	1327
2024 Q2	$393K	Hold	55,223	–	–	0.01%	917
2024 Q1	$151K	Hold	55,223	–	–	﹤0.01%	1152
2023 Q4	$148K	Hold	55,223	–	–	﹤0.01%	1188
2023 Q3	$146K	Hold	55,223	–	–	﹤0.01%	1153
2023 Q2	$155K	Hold	55,223	–	–	﹤0.01%	1184
2023 Q1	$160K	Hold	55,223	–	–	﹤0.01%	1142
2022 Q4	$198K	Hold	55,223	–	–	0.01%	1092
2022 Q3	$178K	Buy	55,223 +34,800	+170%	+$111K	﹤0.01%	1161
2022 Q2	$62K	Buy	20,423 +2,023	+11%	+$9.57K	﹤0.01%	1272
2022 Q1	$154K	Buy	+18,400	New	+$172K	﹤0.01%	1210

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bridgeway Capital Management's CLYM Position: Q2 2026 in Review

Bridgeway Capital Management reduced its Climb Bio (CLYM) stake by 3% in Q2 2026, selling an estimated $41.3K and leaving 130,300 shares worth $1.7M. The position accounts for 0.03% of the portfolio, ranked #613.

Bridgeway Capital Management first reported a position in CLYM in Q1 2022 and has held it in 16 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

Bridgeway Capital Management held 130,300 shares of Climb Bio worth $1.7M as of Q2 2026.
Bridgeway Capital Management sold 4,000 Climb Bio shares in Q2 2026, an estimated $41.3K.
Climb Bio made up 0.03% of Bridgeway Capital Management's portfolio in Q2 2026, its #613 holding.
Bridgeway Capital Management first reported a position in Climb Bio in Q1 2022 and has held it in 16 quarters since.
109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.